首页> 美国卫生研究院文献>International Journal of Health Policy and Management >Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals
【2h】

Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals

机译:药品贸易协议和直接面向消费者的广告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is growing international concern about the risks posed by direct-to-consumer advertising (DTCA) of prescription pharmaceuticals, including via the internet. Recent trade agreements negotiated by the United States, however, incorporate provisions that may constrain national regulation of DTCA. Some provisions explicitly mention DTCA; others enable foreign investors to seek compensation if new regulations are seen to harm their investments. These provisions may thus prevent countries from restricting DTCA or put them at risk of expensive legal action from companies seeking damages due to restrictions on advertising. While the most recent example, the Trans-Pacific Partnership Agreement (TPP), collapsed following US withdrawal in January 2017, early indications of the Trump Administration’s trade policy agenda signal an even more aggressive approach on the part of the United States in negotiating advantages for American businesses. Furthermore, the eleven remaining TPP countries may decide to proceed with the agreement in the absence of the United States, with most of the original text (including the provisions relevant to DTCA) intact.
机译:国际上越来越关注处方药的直接面向消费者的广告(DTCA)所带来的风险,包括通过互联网。但是,由美国谈判达成的最近的贸易协定包含可能限制DTCA国家法规的规定。一些条款明确提到了DTCA;如果新法规被认为损害了他们的投资,则另一些则使外国投资者能够寻求赔偿。因此,这些规定可能会阻止国家限制DTCA或使他们面临因广告限制而寻求损害赔偿的公司提起昂贵诉讼的风险。虽然最近的例子《跨太平洋伙伴关系协定》(TPP)在美国于2017年1月撤军后崩溃了,但特朗普政府贸易政策议程的早期迹象表明,美国方面在采取谈判优势方面采取了更加激进的态度。美国企业。此外,剩余的11个TPP国家可以决定在美国不在的情况下继续执行该协议,而大多数原始案文(包括与DTCA相关的规定)保持不变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号